Investigation of transcript variant 6 of tpd52l2 as a prognostic and predictive biomarker in basal-like mda-mb-231 and mda- mb-453 cell lines for breast cancer

HIGHLIGHTS

• who: Xin Zhang and colleagues from the Department of Spine Surgery, Weifang People's Hospital, Weifang, Shandong, China have published the research: Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA- MB-453 Cell Lines for Breast Cancer, in the Journal: Oxidative Medicine and Cellular Longevity of 29/08/2022
• what: The authors evaluated TPD52L2 expression and its impact on patient outcomes in a breast cancer cohort from To expand the analysis , the authors investigated TPD52L2 expression in patients with luminal A, luminal . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.